Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Henoch-Schönlein purpura nephritis (HSPN), a severe renal manifestation of IgA vasculitis (IgAV), is rare in adults and associated with high morbidity. Current therapies are suboptimal, necessitating novel approaches. This case study evaluates the efficacy of telitacicept—a dual BAFF/APRIL inhibitor approved for systemic lupus erythematosus (SLE)—in a high-risk adult HSPN patient, aiming to explore its potential for IgA-mediated disorders.
We present the case of a 45-year-old male with biopsy-confirmed HSPN(ISKDC IIIb) (Fig.1), progressive renal impairment (baseline eGFR 44 mL/min/1.73 m²; serum creatinine 104.4 μmol/L), and significant proteinuria (1.08 g/day), who was treated with weekly subcutaneous telitacicept (160 mg) in combination with oral prednisone, with clinical outcomes evaluated over a fourteen-month follow-up period.
After fourteen months of therapy, the patient demonstrated rapid and sustained clinical improvement. Proteinuria decreased by 78.7% (from 1.08 g/day to 0.23 g/day), accompanied by a progressive improvement in renal function (serum creatinine reduced to 90.9 μmol/L; eGFR steadily increased during follow-up). Oral prednisone was gradually tapered and discontinued by month six without relapse, while telitacicept was reduced to 160 mg biweekly from month seven onward. Notably, disease control was maintained throughout, underscoring telitacicept’s steroid-sparing capability. No treatment-related adverse events were observed, confirming the favorable safety profile of this regimen.(Fig.2)
Telitacicept exhibited potent efficacy in resolving proteinuria, stabilizing renal function, and enabling corticosteroid withdrawal in refractory HSPN. These findings highlight dual BAFF/APRIL inhibition as a promising targeted strategy for IgA-mediated diseases. Further large-scale studies are warranted to validate its therapeutic role in HSPN.
